Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

Lenvatinib (off Label)

Lenvima

Stage Phase 2

Sponsor Eisai (investigator studies)

Route oral

Modality small molecule

Class VEGFR multi-kinase TKI

Mechanism VEGFR1 to 3, FGFR1 to 4, PDGFRA, KIT, RET inhibitor (label class)

Target VEGFR1 to 3 (KDR, FLT1, FLT4) (TEC-0075)

Target FGFR1 (TEC-0092)

Sources

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e

Lenvima (lenvatinib) USPI, DailyMed setid f4bedd21-efde-44c6-9d9c-b48b78d7ed1e, published 10.22.2026, re-opened 2026-10-27 (raw/dailymed/lenvima.txt). The label has no adenoid cystic carcinoma indication (text search, 0 hits). Safety figures used are from other cancers (SELECT thyroid: dose reductions 68%, discontinuation for adverse reactions 18%) and are class context only.

Brief source A1

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/30939095/

Ho AL et al. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma, J Clin Oncol 2019, doi 10.1200/JCO.18.01859, PMID 30939095 (publication abstract; opened 2026-10-27): 33 enrolled, 32 evaluable; 24 mg daily; 5 partial responses (15.6%), 24 stable disease; median PFS 17.5 months (95% CI 7.2 to not reached; only 8 progression events); 23 patients needed at least one dose modification; 18 of 32 discontinued for drug-related issues; grade 3 or 4 hypertension 28.1%, oral pain 9.4%; three grade 4 events.

Brief source A19

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/32031693/

Locati LD et al. ACC-LEN14, lenvatinib in R/M salivary ACC, Cancer 2020, PMID 32031693 (publication abstract; opened 2026-10-27): 28 enrolled, 26 evaluable, 3 partial responses (11.5%); grade 3 or higher TRAEs 50%; dose reduced in 24 patients; median PFS 9.1 months, OS 27 months, DoR 3.1 months; quality of life deteriorated for fatigue and dry mouth at 6 months, with no change in swallowing or physical functioning. Italian real-world series (Head and Neck 2025, PMID 40033633, abstract opened): 51 patients, ORR 21.7%, grade 3 or higher hypertension 25.5%, stomatitis 17.6%, median OS 16.1 months.

Brief source A20

publication, as of 2026-11-07

https://doi.org/10.1200/jco.2023.41.16_suppl.6048

Lenvatinib plus pembrolizumab in progressive R/M ACC, ASCO 2023 abstract 6048 (doi 10.1200/jco.2023.41.16_suppl.6048; abstract not opened; figures from a search record): 17 evaluable, ORR 6% (1 partial response), below the prespecified threshold; 76% stable disease; grade 3 or higher toxicity 71%. Registry NCT04209660 still active, not recruiting, PCD 2026-12.

Brief source A25

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT02780310

A Phase II Study of Lenvatinib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT02860936

Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT04209660

A Phase II Study of Lenvatinib Plus Pembrolizumab in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Lenvatinib MSK Phase 2

Registry NCT02780310

Phase Phase 2

Status Active, not recruiting

Enrollment 33

Start 2016-05-19

Primary completion 2027-05

Study completion 2027-05

Catalyst Primary completion. 05.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Lenvatinib 24 mg

Dose 24 mg

Regimen once daily

Population progressive R/M ACC (n = 32 evaluable)

Estimand Single arm

objective response rate: 15.6%, primary analysis

median progression-free survival: 17.5 months, 8 progression events

grade 3 or 4 hypertension: 28.1%, primary analysis

discontinued for drug-related issues: 18 patients (of 32), primary analysis

ACC-LEN14

Registry NCT02860936

Phase Phase 2

Status Completed

Enrollment 26

Start 2015-06

Primary completion 2019-06

Study completion 2019-06

Lenvatinib 24 mg

Dose 24 mg

Regimen once daily

Population R/M salivary ACC (n = 26 evaluable)

Estimand Single arm

objective response rate: 11.5%, primary analysis

median progression-free survival: 9.1 months, primary analysis

median overall survival: 27 months, primary analysis

grade 3 or higher treatment-related adverse events: 50%, primary analysis

Lenvatinib + pembrolizumab

Registry NCT04209660

Phase Phase 2

Status Active, not recruiting

Enrollment 64

Start 2020-06-02

Primary completion 2026-12

Study completion 2026-12

Catalyst Primary completion. 12.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Lenvatinib + pembrolizumab

Dose not stated in source

Population progressive R/M ACC (n = 17 evaluable)

Estimand Single arm

objective response rate: 6%, ASCO 2023 (search record)

grade 3 or higher toxicity: 71%, ASCO 2023 (search record)